X
AZ’s Tagrisso wins new NSCLC first-line approval in Europe
https://pharmaphorum.com/news/az-tagrisso-nsclc-egfr-europe/
NSCLC
NICE recommends Pfizer’s Xalkori in rare lung cancer
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
Roche’s Tecentriq combo extends life in advanced NSCLC
Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
Groundbreaking lung cancer approval a big boost for AZ’s Imfinzi
AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.
BMS strikes back with lung cancer combo success
Just as it looked like Bristol Myers Squibb might never catch up with its rivals in frontline lung cancer treatment, the company has achieved success in a new combination.
Interview: AZ’s immunotherapy gamble starts to pay off
Robert Iannone, AstraZeneca’s head of immune-oncology research, on the unpredictable immunotherapy market.
